Portal de investigación
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Cebrian, A
- Gómez Del Pulgar T
- Mendez-Vidal, MJ
- Gonzalvez, ML
- Lainez, N
- Castellano, D
- Garcia-Carbonero, I
- Esteban, E
- Saez, MI
- Villatoro, R
- Suarez, C
- Carrato, A
- Munarriz-Ferrandiz, J
- Basterrechea, L
- Garcia-Alonso, M
- Gonzalez-Larriba, JL
- Perez-Valderrama, B
- Cruz-Jurado, J
- González Del Alba A
- Moreno, F
- Rodriguez-Remirez, M
- Boni, V
- Mahillo-Fernandez, I
- Martin, Y
- Viqueira, A
- Garcia-Foncillas, J
Grupos
Abstract
Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.
Datos de la publicación
- ISSN/ISSNe:
- 2045-2322, 2045-2322
- Tipo:
- Article
- Páginas:
- 41371-41371
- DOI:
- 10.1038/srep41371
- Factor de Impacto:
- 1,533 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
SCIENTIFIC REPORTS NATURE PUBLISHING GROUP
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Proyectos asociados
ESTUDIO RETROSPECTIVO DEL MANEJO DE PACIENTES CON CANCER DE PROSTATA HORMONORESISTENTE AVANZADO. ESTUDIO ESPRO.
Investigador Principal: GASPAR REYNES MUNTANER
SAN-DOC-2010-02 . 2011
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PF299804, UN INHIBIDOR PAN-HER IRREVERSIBLE, EN PACIENTES CON GLIOBLASTOMA RECURRENTE CON AMPLIFICACIÓN DE EGFR O PRESENCIA DE LA MUTACIÓN EGFRVIII .
Investigador Principal: GASPAR REYNES MUNTANER
GEINO-11 . 2012
ENSAYO CLINICO, FASE II ALEATORIZADO DE TRATAMIENTO NEO-ADYUVANTE CON DOS CICLOS DE TEMOZOLOMIDA A DOSIS EXTENDIDAS, PREVIOS AL TRATAMIENTO CON TEMOZOLOMIDA MAS IRRADIACION Y POSTERIOR ADYUVANCIA CON TEMOZOLOMIDA VERSUS MISMO TRATAMIENTO CON BEVACIZUMAB
Investigador Principal: GASPAR REYNES MUNTANER
GENOM-009 . 2010
Cita
Cebrian A,Gómez Del Pulgar T,Mendez MJ,Gonzalvez ML,Lainez N,Castellano D,Garcia I,Esteban E,Saez MI,Villatoro R,Suarez C,Carrato A,Munarriz J,Basterrechea L,Garcia M,Gonzalez JL,Perez B,Cruz J,González Del Alba A,Moreno F,Reynes G,Rodriguez M,Boni V,Mahillo I,Martin Y,Viqueira A,Garcia J. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017. 7. p. 41371-41371. IF:4,122. (1).